Comparative Pharmacology
Head-to-head clinical analysis: EXALGO versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXALGO versus PALLADONE.
EXALGO vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic